Investors > News Releases
Jan 04, 2019
GeneSight® GUIDED Study Published in the Journal of Psychiatric Research
Products
Dec 31, 2018
Peter D. Meldrum (1947-2018)
Corporate
Dec 27, 2018
Myriad Genetics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Corporate
Dec 26, 2018
Myriad Announces Publication of Vectra® Study in Journal Rheumatology
Products
Dec 19, 2018
BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Stage, BRCA-Mutated Ovarian Cancer
Products
Dec 19, 2018
EndoPredict® Test Receives Positive NICE Recommendation for Patients with Early Breast Cancer
Products
Dec 07, 2018
Prospective Study Demonstrates EndoPredict® Can Guide Chemotherapy Decision For Women with Early-Stage Breast Cancer
Products
Dec 07, 2018
Myriad Announces Important New Data for Its EndoPredict® Breast Cancer Test Will Be Presented at the 2018 San Antonio Breast Cancer Symposium
Products
Dec 06, 2018
Myriad Validates Polygenic Score to Predict Breast Cancer Risk in Women of Hispanic Ancestry Who Test Negative for Hereditary Cancer Mutations
Products
Nov 19, 2018
Myriad Announces $50 Million Accelerated Share Repurchase Program
Corporate
Nov 12, 2018
Myriad to Present New Data from Its Industry-Leading Portfolio of Genetic Tests for Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Products
Nov 06, 2018
Myriad Genetics Reports Fiscal First-Quarter 2019 Financial Results
Financial
Nov 05, 2018
Myriad Receives the Prestigious 2018 Utah Top Workplaces Award
Corporate
Nov 02, 2018
Myriad Presents Two New Studies at the Western Section of the American Urological Association
Products
Oct 30, 2018
Myriad Genetics to Present at the Stephens New York Investment Conference
Financial